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surroundedbyreactivesmoothmusclecells (4) .Thelesioncan beeitherfocalordiffuse,butitismostlylocatedintheposteriorwalloftheuterinecorpus (5) .Itisoneofthemost common accompanying histopathologic findings of EC, particularly of endometrioid histotype, with a varying incidence of 12% to 66% (6) (7) (8) . Since both conditions share a common etiologic factorofhyperestrogenism (4, 9) ,ithasbeensuggestedthat similarmolecularmechanismsmayberesponsibleforthedevelopmentofthese2entitiesoroneconditionmaypromote developmentoftheotherone (7) .Arecentpopulation-based studythatfollowedupover750patientswithpureadenomyo-sisfora5-yearperioddemonstratedthatadenomyosisisassociatedwitha5-foldincreaseintheriskofdevelopingEC (10) .
Despite the common occurrence of adenomyosis in EC, thereisapaucityandconflictintheliteratureregardingits effect on outcomes of patients. While some researchers foundthatECsaccompaniedbythishormone-dependentbenignlesionhavefavorableprognosis (11, 12) ,othersreported thatithasnoimpactondiseaserecurrenceormortalityrates (7, 8) . In the current study, in order to assess the independent relationship of adenomyosis and disease outcomes in Adenomyosis is a benign lesion characterized by intramyometrial presence of endometrial glands and stroma endometrioid type EC, we compared disease-free survival (DFS),overallsurvival(OS),anddisease-specificsurvival(DSS) betweenage-,tumorgrade-,andstage-matchedcohortswith andwithoutadenomyosis.
Methods
Thestudywasconductedusingclinicopathologicdataof 314 consecutive patients with endometrioid type EC who underwent staging surgery at a single institution between August2005andNovember2014.
Data including age, coexistence of adenomyosis, grade, depth of myometrial invasion, tumor size, lymphovascular spaceinvolvement(LVSI),lymphnodeinvolvement,stageof the disease, adjuvant therapy, disease recurrence, and diseasestatusonthedateofthelastfollow-upwerecollected fromtheinstitutionaldatabaseandpatientchartsfollowing institutionalreviewboardapproval.
Patientsweredividedinto2groupsaccordingtothepres-ence(n=79)orabsence(n=235)ofadenomyosis.Atotalof 80 patients who were lost to follow-up or had synchronous malignancywereexcludedfromfurtheranalyses.Finally,the adenomyosis-positive group consisted of 70 patients while theadenomyosis-negativegroupconsistedof164patients.A propensity score-matched analysis was carried out to obtain matched cohorts of patients with and without adenomyosis, andthus,tominimizeselectionbias.Thepropensityscorewas developedthroughmultivariablelogisticregressionmodelincludingageatsurgery,stageofthedisease,andtumorgradeas covariates.Analysiswasperformedas1-to-1propensityscore-matched,withoutreplacementonthebasisoftheestimated propensityscoreofeachpatient.Thematchtolerancewasset at 0.01. After performing propensity score matching, 70 patientsfromeachgroupweresuccessfullymatched (Fig.1) .
TheprimaryoutcomeofthestudywasDFS,andthesecondaryoutcomeswereOSandDSS.Thedifferencesbetween 2groupsweretestedbyunpairedttestsforparametricdata andMann-WhitneyUtestfornonparametricdata. Chi-square or Fisher exact tests were used for comparison of categorical variables. The DFS, OS, and DSS within the first 3 and 5 years after the primary surgery were estimated using the Kaplan-Meiermethod.TheDFSwasmeasuredfromthedate of surgery to the date of disease recurrence or death from anycause;OS,fromthedateofsurgerytothedateofdeath fromanycause;andDSS,fromthedateofsurgerytothedate ofdeathcausedbythedisease.Thelog-ranktestwasusedto compareKaplan-Meiercurves.TheCoxproportionalhazards regressionmodelwasusedtoestimatehazardratios(HR)and 95%confidentialintervals(CI).Allstatisticaltestswere2-sided withasignificancethresholdofp<0 .05,andperformedusing IBM-SPSSversion20.0forMacOS. 
Results

TableIdisplaystheclinicalandpathologiccharacteristics
Discussion
Studies regarding the association of adenomyosis with ECintheliteraturemostlyfocusedontheeffectofadenomyosis on primary tumor characteristics, with conflicting results. Some studies reported that when compared with tumors without adenomyosis, ECs coexisting with adenomyosisarenotonlymorelikelytoinvadethemyometrium butaresignificantlymorepronetoachievedeepmyoinvasion (8, 13) . However, others reported that coexistent adenomyosis in EC is associated with less aggressive tumor characteristicsincludingsuperficialmyoinvasion,lowtumor grades, small tumor size, negative LVSI, or negative lymph nodestatus(6,7,11,12). 
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A similar discrepancy also exists among studies in which the outcomes of patients with EC coexisting with and withoutadenomyosiswerecompared.Musaetal(7)investigated thediseaseoutcomesin197patientswithendometrioidEC, ofwhom130(66%)hadadenomyosis.Althoughtheauthors initiallyfoundasignificantlyimprovedsurvivalinpatientswith adenomyosis,theyconcludedthatwhencontrollingforgrade anddepthofmyoinvasion,thepresenceofadenomyosishad noindependenteffectonsurvival.Similarly,inastudyconsistingof362casesofendometrioidEC,ofwhom121(33.4%)had adenomyosis,Taneichietal(8)reportedthatbothinearlyand advancedstages,therewerenosignificantdifferenceswithrespecttoPFSorOSbetweenthe2groups;instageI-IIdisease, 5-yearPFSwas89%vs93%and5-yearOSwas100%vs95.5% forpatientswithandwithoutadenomyosis,respectively.
Incontrast,2otherstudiesfoundabetterprognosisfor patientswithadenomyosisthanforthosewithout.Koshiyamaetal(11)examinedtheoutcomesof179patientswithEC, consistingof29(16%)caseswithadenomyosis,12caseswith endometriosis,51caseswithmyomauteri,and87controls withoutthesebenigndiseases.Theauthorsreportedthatthe bestdiseaseoutcomewasforthepatientswithECsaccompaniedbyadenomyosis,followedbypatientswithendometriosis,patientswithmyomauteri,andthenthecontrolpatients. Inamorerecentstudy,Matsuoetal(12)evaluatedthesignificanceofcoexistentadenomyosisinalarge-scalecomprehensive analysis. The study included 571 patients with EC with varyingtumorhistotypes;adenomyosiswasevidentinnearly halfofthepatients(n=271,47.5%).Theauthorsfoundthat ECscoexistingwithadenomyosiswereassociatedwithasignificantly better 5-year DFS (89% vs 78%; p<0.001) and OS (91% vs 83%; p = 0.004) when compared with ECs without adenomyosis. They also noted that coexistent adenomyosis was an independentpredictor of DFS, though it did not remainsignificantforOSonmultivariateanalysis.
Interpretation of these trials is rather problematic due to the heterogeneity in tumor characteristics between the groups.EspeciallyinthestudyofKoshiyamaetal(11),while patientsintheadenomyosisgrouphadendometrioidhistotype and stage I disease only, other groups included some nonendometrioid histologies and advanced stage tumors. Similarly,inthestudybyMatsuoetal (12) ,studygroupswere significantlydifferentwithrespecttotumorgrade,myometrialinvasion,andstageofthedisease.
The current study demonstrated that coexistent adenomyosishasnoprognosticimpactonoutcomesofpatientswith endometrioid EC after adjustment for major confounders includingage,tumorgrade,andstageofthedisease.Ourstudy differs from the previous ones with its advanced statistical approachofpropensityscorematching.Theanalysisofapropensityscore-matchedsamplecanmimicthatofarandomized controlledtrial (14) .Whenestimatingtreatmenteffectsusing observationaldata,thismethodallowsremovingtheeffectsof confoundingthatcanoccurduetodifferencesinthedistribution ofmeasuredbaselinecovariatesbetweentreatmentgroups.
Theanalysespresentedinourstudyhavelimitations.The lackofanalysisofotherpotentialconfounders,suchascomorbidities,menopausalstatus,obstetrichistory,obesity,andseverityofadenomyosis,mighthaveaffectedourfindings. Another limitation is the lack of pathology review to discriminate ECs coexistingwithadenomyosisfromECsarisingfromfociofadenomyosis, as these 2 conditions are pathologically and clinically distinct, with different diagnostic criteria and biological behaviors.Endometrialcancerarisinginadenomyosis(EC-AIA) ishistologicallycharacterizedbythedemonstrationofadenocarcinomaintheepitheliumoftheadenomyosisfociwithno evidenceofcarcinomainthenormallysituatedendometrium. ThepresenceorabsenceofECintheeutopicendometriumis simply the essential determinant of differential diagnosis between these 2 entities (15) . In contrast to relatively common occurrenceofECcoexistingwithadenomyosis,EC-AIAisarare condition, with only 46 reported cases in the literature as of 2015 (16) .Whencomparedwithtumorswithoutadenomyosis, ECs-AIAaremorelikelytohavedeepmyometrialinvasion,nonendometrioidhistology,andpoorDFS (16) .Arecentsystematic review comparing disease outcomes between ECs coexisting withadenomyosisandECs-AIAalsorevealedthataftercontrollingforgrade,stageofthedisease,andhistotype,ECs-AIAare significantly associated with poor DFS (HR 2.87; 95% CI 1.44-5.70;p=0.031) (17) .Despitethelackofpathologyreviewinour study, the primary pathologic examinations of all cases were performedbypathologists,whohadgynecopathologysubspecialty,andtherewasnocasewithadiagnosisofEC-AIA.
In conclusion, in the present study we investigated whether there is an independent relationship between the presenceofadenomyosisanddiseaseoutcomesinpatients with endometrioid type EC. We determined that coexistent adenomyosis in EC is not a prognostic factor and does not affectsurvivaloutcomes.Furtherresearchisneededtoclarify theclinicalandpathologicfeaturesoftumorsarisinginthe fociofadenomyosis.
Theabstractofthisstudywasacceptedasaposterpresentationatthe20 th InternationalMeetingoftheEuropean SocietyofGynaecologicalOncology(ESGO2017);November 4-7,2017;Vienna,Austria. 
